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Abstract
Background: Concern for MRSA in patients presented to the hospital with pneumonia may be overestimated
leading to excessive prescribing of empiric anti-MRSA therapy. This study aims to identify at-risk patients and
treatment outcomes.
Methods: Adults hospitalized during 2005–2011 with pneumonia diagnosed within 48 h of admission were included.
Medical charts were retrospectively reviewed for relevant data. Patients with MRSA were matched 1:1 to those with
non-MRSA pathogen or negative culture. A published risk scoring system for MRSA pneumonia was applied.
Results: 268 elderly patients were included, 134 patients in each group. Compared to non-MRSA group, MRSA patients
presented more acutely ill (p < 0.0001) (pneumonia severity index score, 150 vs 93; vasopressor therapy, 34% vs 6%; ICU
admission, 47% vs 13%; and mechanical ventilation, 35% vs 10%) and had worse outcomes (p < 0.0001) (time to reach
clinical stability, 6 vs 2.5d; length of stay, 10 vs 5d; clinical failure, 28% vs 4%; 28-day mortality, 22% vs 3%). When applied
to our patients, a published risk scoring scheme had 93% sensitivity but lacked specificity at 55%; 40% of medium-risk
patients did not have MRSA. A history of MRSA infection or pneumonia differentiated the latter group. Most MRSA
patients (66%, 88/134) were treated empirically (primarily vancomycin) but outcome was not improved by receipt of
empiric therapy.
Conclusions: Use of a published risk scoring scheme with additional variables from this study can potentially reduce
overprescribing of anti-MRSA empiric therapy in patients presented to the hospital with pneumonia. Prospective studies
evaluating the treatment benefit of non-vancomycin alternatives as empiric therapy are needed.
Keywords: Pneumonia, Methicillin-resistant Staphylococcus aureus, Community-onset pneumonia,
Healthcare-associated pneumonia, Risk factors
Background
Recent epidemiologic investigations indicate that the preva-
lence of community-associated (CA)-MRSA infections is
rising, though most involve skin and soft tissue infections
[1,2]. While the actual incidence of MRSA in community-
acquired pneumonia remains low, the incidence of MRSA
in healthcare-associated pneumonia (HCAP) accounts for
28% of healthcare-associated cases [3] and exceeds that in
all pneumonia types including ventilator-associated pneu-
monia (VAP) [4,5]. Patients with risk factors for HCAP
constitute a heterogeneous group with varying risk for
drug-resistant gram-positive versus gram-negative patho-
gens depending on functional status and type and extent of
healthcare exposure [6,7]. Concern for MRSA in patients
presenting to the hospital with pneumonia may be overesti-
mated, leading to excessive prescribing of empiric anti-
MRSA therapy [5].
Shorr et al. recently published a scoring system to strat-
ify patients presenting to the hospital with pneumonia to
predict their risk for MRSA infection [8]. The risk score
was developed based on a retrospective analysis of 5,975
adult patients from 62 US hospitals who had an ICD-9
code for pneumonia diagnosed within 48 h of admission
of a bacterial etiology; of those 837 (14%) had MRSA
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pneumonia. The study cohort was split into a develop-
ment and validation cohort to create the risk score. The
scoring system consisted of eight variables: age <30
or >79 years, recent hospitalization, nursing home ex-
posure within the last 90 days, prior IV antibiotic therapy
within the last 30 days, ICU admission, cerebrovascular
disease prior to admission, dementia, and female with dia-
betes; and ranged from scores of 0–10. The risk for MRSA
is <10% for score of 0 or 1 compared to >30% for score
of ≥6. However, the study did not evaluate outcomes
associated with treatment prescribed in the different risk
groups. If externally validated, this scoring system has the
potential to aid clinicians in targeting empiric anti-MRSA
therapy based on risk for MRSA infection.
Our study aimed to evaluate patients with community-
onset pneumonia defined as patients presenting to the
hospital with pneumonia with or without healthcare ex-
posure by: 1) comparing the clinical and epidemiologic
characteristics of patients with MRSA versus non-MRSA
pneumonia, 2) testing the utility of Shorr’s scoring system
in identifying patients at risk for MRSA, and 3) evaluating
outcomes observed with empiric anti-MRSA therapy in
high risk patients.
Methods
This was a retrospective cohort study conducted at a 625-
bed community-teaching hospital in Pasadena, California.
The study protocol was approved by the Huntington
Hospital Institutional Review Board. Patients hospital-
ized between January 2005 and October 2011 were
screened by ICD-9 codes for pneumonia (481.X-486.X)
and included if they were: 1) ≥18y, 2) diagnosed with
pneumonia per CDC criteria [9] within 48 h of hospital
admission, 3) had a respiratory culture taken, and 4) re-
ceived ≥ 48 h of effective therapy. Patients with multiple
organisms in the respiratory culture were excluded. Pa-
tients were split into two groups, those with the causative
organism being MRSA vs a non-MRSA pathogen or a
negative culture. Since there were many more non-MRSA
pneumonia patients, those who met inclusion criteria were
randomly selected to match the MRSA pneumonia
patients by number. HCAP was defined per the 2005
Infectious Diseases Society of America’s hospital-acquired
pneumonia (HAP), VAP and HCAP guidelines [10].
Medical charts were reviewed to obtain relevant demo-
graphic, laboratory, radiographic, and clinical information:
age; comorbid conditions; prior history of pneumonia
within 1 year; history of healthcare exposure or prior
antibiotic exposure within 90 days per medical records or
stated in the patient history; any history of MRSA infec-
tion or colonization; presence of severe sepsis requiring
vasopressor support; antibiotic therapy prescribed during
the admission (timing and regimen); radiographic, labora-
tory, and clinical progress; culture and sensitivity results;
length of stay; death within 28 days of pneumonia diagno-
sis; and hospital readmission within 30 days of discharge.
Disease severity was assessed using Acute Physiology and
Chronic Health Evaluation (APACHE) II score within
24 hours of admission and Pneumonia Severity Index
(PSI). The data were recorded on a structured data collec-
tion form and entered into Microsoft Access.
Data analysis
Patients were grouped by respiratory culture results for
MRSA vs non-MRSA; the latter group included those with
negative cultures. Demographic and clinical variables and
severity of presentation were compared to identify differ-
entiating characteristics. Patients were stratified into high,
medium, and low risk groups for MRSA using the risk
scoring system by Shorr et al. [8]. Notably, history of
dementia used in the scoring system was substituted in
this study by presence of feeding tube and Intensive
Care Unit (ICU) admission was recorded for any time
during the hospital stay. Sensitivity, specificity, positive
and negative predictive values were calculated to valid-
ate the risk scoring system.
The choice and timing of anti-MRSA therapy prescribed
during admission was compared between groups. Out-
come measures were: time to achieve clinical stability [11],
clinical response at end of treatment, need for and dur-
ation of mechanical ventilation, total length of stay, 28-day
mortality, and 30-day readmission. Clinical response was
determined as complete if resolution or partial if improve-
ment was noted with fever, leukocytosis, and signs and
symptoms of pneumonia.
Statistical analysis
Univariate analysis was performed using Wilcoxon rank
sum tests for non-parametric continuous data or inde-
pendent t-test for parametric continuous data and Fisher’s
exact test and chi-square test for categorical data where
appropriate using GraphPad Prism v4.0 (San Diego, CA,
USA) or SAS version 9.3 (SAS Institute, Cary, NC). A p
value < 0.05 denotes statistical significance. To assess for
the most significant predictors for MRSA pneumonia, PSI
score, residence prior to admission, presence of other
infections at admission, prior antibiotic exposure within
90 days, and presence of feeding tubes were modeled in a
multivariate logistic regression analysis controlling for age,
APACHE II, and ≥3 comorbid conditions. In order to as-
sess the most significant predictors of death in the MRSA
pneumonia group, a multivariate logistic regression ana-
lysis controlling for APACHE II score was performed with
the inclusion of the following variables: receipt of empiric
anti-MRSA therapy, presence of renal dysfunction, need
for mechanical ventilation, and vasopressor requirement.
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Results
Patient characteristics and risk factors
A total of 1,615 patients with ICD-9 code for pneumo-
nia were screened. Patients were excluded for diagnosis
of pneumonia >48 h after admission (n = 128), incom-
plete medical record (n = 66), <48 h of antimicrobial ther-
apy (n = 99), did not meet CDC criteria for pneumonia
(n = 241), multiple organisms in the respiratory culture
(n = 482) or none taken (n = 288). A total of 311 patients
met inclusion criteria; 134 patients had MRSA pneumo-
nia. An equal number of patients with non-MRSA pneu-
monia were randomly selected to match the MRSA group
by number. Twenty-eight patients in the non-MRSA
pneumonia group had a bacterial etiology: P. aeruginosa
(n = 7), Enterobacter spp (n = 3), methicillin-sensitive S.
aureus (n = 3), S. pneumoniae (n = 3), Acinetobacter spp
(n = 2), S. pyogenes (n = 2), Haemophilus spp. (n = 1),
Stenotrophomonas maltophilia (n = 1), Legionella (n = 1).
Overall, the study cohort was elderly with a median age
of 79 y and 48% were male. The most common comorbid
condition was cardiovascular disease (66%), followed by
pulmonary diseases (32%). Patients with MRSA vs non-
MRSA pneumonia had distinct demographic and clin-
ical characteristics compared to those with non-MRSA
pneumonia (Table 1). MRSA patients were more likely to
have ≥3 comorbid conditions (64% vs 30%, p < 0.0001), dia-
betes (33% vs 19%, p < 0.0001), cerebral vascular accident
(CVA) (31% vs 7%, p < 0.0001), and renal disease (16% vs
6%, p = 0.011) than patients with non-MRSA pneumo-
nia. Notably, majority of the MRSA patients (73% vs
17%, p < 0.0001) resided in a skilled nursing facility
(SNF) prior to admission and half had enteral feeding
tubes.
Healthcare exposure within 90 days and prior anti-
biotic exposure were significantly more prevalent in
the MRSA than the non-MRSA group: 90% vs 37% and
52% vs 17%, respectively (p < 0.0001). Furthermore,
prior history of pneumonia within 1 year of admission
(42% vs 12%) and a history of MRSA infection (20% vs
0.7%, p < 0.0001; predominantly pneumonia) were al-
most exclusively present in the MRSA group. Notably,
41% of the MRSA group had other infections at the
time of admission compared to 10% in the non-MRSA
group. When the above risk factors were included in a
multivariate regression model, residence in a SNF prior
to admission (OR 5.30, CI 2.59-10.87) and prior anti-
biotic exposure within 90 days (OR 4.62, CI 2.16-9.91)
were the two most significant predictors of MRSA
pneumonia (Table 2).
MRSA pneumonia patients presented more acutely ill
compared to the non-MRSA group (p < 0.0001) as evi-
dent by the higher APACHE II scores and more patients
in PSI class IV and V and admitted to the ICU with need
for vasopressor therapy and mechanical ventilation.
Table 1 Demographics and patient characteristics
Characteristics MRSA
pneumonia
n = 134 (%)
Non-MRSA
pneumonia
n = 134 (%)
p value
Demographics
Age [median (IQR)] 82 (71.5, 89) 75.5 (62, 85) 0.0002
Male 67 (50) 62 (46) 0.62
Residence prior to admission
Home 35 (26) 110 (82) < 0.0001
SNF 98 (73) 23 (17) < 0.0001
Other hospital 1 (0.7) 1 (0.7) 1
APACHE II [median (IQR)] 15 (11,20) 10 (7,13) <0.0001
Comorbid conditions
Cardiovascular diseasea 92 (69) 84 (63) 0.37
Diabetes 44 (33) 26 (19) <0.0001
Cerebrovascular accident (CVA) 41 (31) 9 (7) <0.0001
Liver diseaseb 6 (4) 4 (3) 0.74
Renal diseasec 22 (16) 8 (6) 0.011
Pulmonary diseased 47 (35) 39 (29) 0.24
Malignancy 21 (16) 14 (10) 0.37
≥3 comorbid conditions 86 (64) 40 (30) <0.0001
Healthcare exposure history
History of MRSA infection 27 (20) 1 (0.7) <0.0001
History of MRSA pneumonia 14 (10) 0 <0.0001
Prior healthcare exposure
(within 90 days)
120 (90) 50 (37) <0.0001
Prior antibiotic exposure
(within 90 days)
70 (52) 23 (17) <0.0001
Days since last antibiotic given
[median (IQR)]
24 (7,41) 7 (0,32) 0.629
Prior history of pneumonia
within 1 year
56 (42) 16 (12) <0.0001
Presence of feeding tube 67 (50) 15 (11) <0.0001
Presence of feeding tube
plus history of CVA
26 (19) 4 (3) <0.0001
Clinical presentation
Presence of other infections
on admission
55 (41) 13 (10) <0.0001
Admission of intensive care units 63 (47) 18 (13) <0.0001
Sepsis requiring vasopressor
support
45 (34) 8 (6) <0.0001
Need for mechanical ventilation 47 (35) 14 (10) <0.0001
PSI class IV or V 123 (92) 71 (53) <0.0001
NOTE: SNF = skilled nursing facility; PSI = Pneumonia Severity Index; APACHE=
Acute Physiology and Chronic Health Evaluation; IQR = interquartile range;
aHypertension, congestive heart failure, prior myocardial infarction, coronary
artery disease; bTotal bilirubin >2.5 mg/dL; cScr >2, Chronic Kidney Disease stage
3 or worse; dChronic obstructive pulmonary disease, emphysema, asthma.
Fisher’s exact or Chi-square test done for categorical variables; p value < 0.05
denotes significance.
Wilcoxon-Mann–Whitney test done for continuous variables, p value < 0.05
denotes significance.
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Utility of Shorr’s risk score
When patients were stratified by Shorr et al’s risk scoring
scheme, 55% of the patients with non-MRSA pneumonia
were deemed to have low risk (scores 0–1) compared to
93% of MRSA patients to have medium (64%, scores 2–5)
or high risk (29%, scores 6–10). A risk score of >1
(medium-high risk) had a 93% sensitivity but lacked speci-
ficity (55%). The negative and positive predictive values
were 89% and 68%, respectively. Notably, 40% of the pa-
tients with a medium risk score did not have MRSA pneu-
monia. Additional variables that significantly differentiated
the medium-risk patients with MRSA versus non-MRSA
infection were: APACHE II score, PSI class IV and V, need
for vasopressor therapy, presence of other infections at
admission, history of MRSA infection, and prior history of
pneumonia within 1 year of admission (Table 3).
Treatment
Sixty six percent (88/134) of the MRSA pneumonia group
received empiric anti-MRSA therapy, most (85%, 75/88)
by 8 h, 11% (10/88) by 24 h, and 3% (3/88) by 48 h of
admission (Table 3). Vancomycin was the most frequently
prescribed agent (60%, 53/88) for the entire treatment
duration; 18 patients switched from vancomycin to
linezolid 96 hours after the start of therapy while 14
patients had linezolid as primary therapy. (data not
shown) Patients without empiric anti-MRSA therapy
had a median delay of 3 days (IQR 2, 5) before receiv-
ing anti-MRSA therapy.
Notably, 28% (38/134) of non-MRSA patients were
also prescribed empiric anti-MRSA therapy. Interest-
ingly, 97% (37/38) of these patients were classified as
having low (15/38) or medium risk (22/38) of MRSA
pneumonia per Shorr’s scoring scheme. Overprescribing
of anti-MRSA therapy in non-MRSA patients could
potentially be reduced from 28% to 3% if either history
of MRSA infection or prior history of pneumonia within
1 year of admission is applied.
Outcomes
Patients with MRSA pneumonia had significantly worse
outcomes overall: prolonged time to reach clinical stability
(6d vs 2.5d) and length of stay (10d vs 5d) as well as lower
rates of clinical response (67% vs 97%) and higher 28-day
mortality (22% vs 3%) (all p < 0.0001) (Table 3). Those clas-
sified as having low risk for MRSA (n = 83) had the most
favorable outcome compared to those having medium (n =
144) and high (n = 41) risk, with increasing rates of clinical
failure (1% vs 19% vs 34%), 28-day mortality (0% vs 15% vs
27%) and 30-day readmission (6% vs 13% vs 15%) respect-
ively (Table 3). Time to reach clinical stability (2d vs 5d vs
7d) and length of stay for survivors (5d vs 9d vs 10d) also
followed the same trend when comparing low, medium
and high risk patients.
Patients with MRSA pneumonia were more likely to
have received empiric anti-MRSA therapy (n = 88) if they
were sicker at presentation with higher APACHE II (18 vs
13; p < 0.0001), PSI scores (153.4 vs 131.3, p = 0.0011),
ICU admission (55%, 48/88 vs 33%, 15/46, p = 0.02), and
need for vasopressor therapy (42%, 37/88 vs 17%, 8/46,
p = 0.0041); and if they were from a SNF (82%, 72/88 vs
57%, 26/46, p = 0.0043). Despite receipt of empiric therapy
in this sicker cohort, worse outcomes were observed with
a higher rate of clinical failure (34% vs 17%, p = 0.046) and
28-day mortality (27% vs 11%, p = 0.29) (Table 4). The po-
tential benefit of empiric treatment on outcome may have
been confounded by severity of pneumonia presentation.
In a subgroup analysis of the sicker patients with severity
scores greater than the mean of APACHE II score ≥18
and PSI score ≥153, outcomes did not differ with respect
to length of stay, the rate of clinical failure and mortality but
30-day readmission rate was significantly higher in the de-
layed treatment group (50% vs 6%, p = 0.02). By multivariate
analysis controlling for underlying severity of illness as mea-
sured by APACHE II score, those who received empiric
therapy had a 1.6 fold higher risk of death compared to
directed therapy, although not statistically significant (p =
0.45) (Table 5). The need for vasopressor was the most sig-
nificant risk factor predictive of death (OR 3.602, p = 0.037).
Among those with MRSA pneumonia and classified as
“high risk” (n = 39), empiric anti-MRSA therapy did not
reduce 28-day mortality, clinical failure, and readmission
rates. However, without empiric therapy, patients had lon-
ger hospital stay (17d vs 9d, p = 0.03) and time to reach
clinical stability (12.5d vs 6d, p = 0.1). Vancomycin was the
primary agent prescribed empirically in over half of those
patients (21/39). The number of remaining patients who
were initiated with or switched to linezolid was too small
to allow for meaningful comparisons.
Discussion
Concerns for the spread of CA-MRSA have led to wide-
spread prescribing of empiric anti-MRSA therapy for
Table 2 Risk factors predictive of MRSA pneumonia by
multivariate logistic regression
Variable OR (95% CI) p-value
Age 0.995 (0.970 - 1.021) 0.7119
APACHE II 1.035 (0.972 - 1.103) 0.2833
≥3 comorbid conditions 1.947 (0.975 - 3.888) 0.0588
PSI IV & V 3.827 (1.260 - 11.626) 0.0179
Residence in SNF prior to admission 5.301 (2.585 - 10.870) <0.0001
Presence of other infections
at admission
3.686 (1.515 - 8.967) 0.0040
Prior antibiotic exposure within 90 days 4.624 (2.158 - 9.909) <0.0001
Presence of feeding tubes 2.357 (1.062 - 5.231) 0.0350
NOTE: PSI = Pneumonia Severity Index; APACHE = Acute Physiology and
Chronic Health Evaluation.
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patients presented to the hospital with pneumonia.
Therefore our study aimed to identify differentiating
characteristics for MRSA pneumonia and evaluate out-
comes associated with empiric anti-MRSA therapy. Our
study cohort involved an elderly population who dif-
fered significantly between those with MRSA vs non-
MRSA pneumonia on risk factors, severity of presentation,
and outcomes. Jung et al. published a retrospective study
of community-onset MRSA vs non-MRSA pneumonia in
a similar patient population and found comparable rates
of mortality and length of stay, though antibiotic treat-
ment was not evaluated [12].
Shorr et al. recently published a risk score assessment to
aid clinicians in identifying those at risk for MRSA among
patients presenting to the hospital with pneumonia. When
applied to our study cohort, the scoring scheme had a posi-
tive predictive value of 68%, predicting those with non-
MRSA pneumonia to have low risk and those with MRSA
Table 3 Clinical characteristics, empiric treatment, and outcomes of patients stratified by risk for MRSA
Stratification by Shorr risk scoring scheme
Low risk (0–1) Medium risk (2–5) High risk (6–10)
MRSA
n = 9 (%)
Non-MRSA
n = 74 (%)
P value MRSA
n = 86 (%)
Non-MRSA
n = 58 (%)
P value MRSA
n = 39 (%)
Non-MRSA
n = 2 (%)
P value
Variables used in Shorr’s risk scoring scheme
Age [median (IQRa)] 66 (61,76) 74.5 (61,84.3) 0.42 84 (72.8, 89.3) 77 (63.5,85.3) 0.01 82 (76,93) 85.5 (82,89) 0.7
Recent hospitalization
within 90 d
0 0 27 (31) 26 (45) 0.12 35 (90) 1 (50) 0.23
Prior antibiotic
exposure in last 30 d
0 2 (3) 1 20 (23) 8 (14) 0.2 22 (56) 1 (50) 1
SNF 5 (56) 3 (4) 0.0002 63 (73) 18 (31) <0.0001 30 (77) 2 (100) 1
Admission into ICU 0 0 34 (40) 16 (28) 0.16 29 (74) 2 (100) 1
History of CVA 0 1 (1) 1 23 (27) 8 (14) 0.1 18 (46) 1 (50) 1
Female with diabetes 1 (11) 3 (4) 0.37 15 (17) 9 (16) 0.82 9 (23) 0 0.07
Additional variables identified in this study (not included in Shorr’s risk scoring scheme)
APACHE II [median (IQR)] 11 (8,18.5) 9 (7,11) 0.1 15 (11, 19.3) 12 (8,17) 0.006 18 (13,22) 21.5 (21,22) 0.52
PSI IV and V 8 (89) 31 (42) 0.01 78 (91) 38 (66) 0.0004 37 (95) 2 (100) 1
Vasopressor 0 0 25 (29) 6 (10) 0.0075 20 (51) 2 (100) 0.49
Mechanical ventilation 1 (11) 0 0.11 27 (31) 13 (22) 0.26 19 (49) 1 (50) 1
Prior antibiotic exposure in last 90 d 1 (11) 3 (4) 0.37 29 (34) 19 (33) 1 35 (90) 1 (50) 0.23
History of MRSA infection 1 (11) 1 (1) 0.2 19 (22) 0 <0.0001 7 (18) 0 1
History of pneumonia 1 (11) 5 (7) 0.5 33 (38) 10 (17) 0.009 22 (56) 1 (50) 1
Presence of other
infections at admission
1 (11) 1 (1) 0.2 36 (42) 11 (19) 0.006 18 (46) 1 (50) 1
Presence of feeding tube 0 0 32 (37) 13 (22) 0.07 34 (87) 2 (100) 1
Treatment
Empiric anti-MRSA therapy 3 (33) 15 (20) 0.4 58 (67) 22 (38) 0.0006 27 (69) 1 (50) 0.54
Vancomycin 2 (67) 15 (100) 0.17 53 (62) 20 (91) 0.002 21 (54) 1 (100) 1
Other agents 1 (33) 0 5 (6) 2 (9) 0.7 6 (15) 0 1
Outcomes
Time to stability [median days (IQR)] 4 (3,11) 1 (1,4) 0.03 6 (4,10) 4 (1,7) 0.052 6.5 (5.3,12.8) 9.5 (0,19) #
Clinical failure 1 (11) 0 0.11 23 (27) 5 (9) 0.0092 14 (36) 0 0.54
Mortality 28-day 0 0 18 (21) 4 (7) 0.03 11 (28) 0 1
LOSb survivors
[median days (IQR)]
9.5 (7,15) 4.5 (3,7) 0.0005 10 (7,14) 7 (5,14.3) 0.1 10 (6,17) 12.5 (5,20) 0.93
Readmission 30-day 2 (22) 3 (4) 0.09 10 (12) 9 (16) 0.65 6 (15) 0 1
NOTE: aIQR = interquartile range; bLOS = length of stay; CVA = cerebral vascular accident; SNF = skilled nursing facility; PSI = Pneumonia Severity Index;
APACHE = Acute Physiology and Chronic Health Evaluation; # n too small.
Chi-square test done for categorical variables; p value < 0.05 denotes significance.
Wilcoxon-Mann–Whitney test done for all continuous variables; p value < 0.05 denotes significance.
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pneumonia to have high risk reasonably well. However,
majority of patients fell within the medium risk group.
Applying additional differentiating criteria identified
from our study (e.g. history of MRSA infection or his-
tory of pneumonia within 1 year) reduced the number
of non-MRSA patients in the medium risk group from
43% to 7%. Also, addition of the PSI class to the scoring
scheme helped capture the small number of patients
with MRSA pneumonia who were “falsely” deemed to
have low risk as 89% of them had PSI IV or V compared
to 42% in the non-MRSA group.
The 2005 Infectious Diseases Society of America guide-
line definition of HCAP has been criticized for its lack of
specificity in identifying risks for resistant pathogens [8],
leading to overprescription of broad-spectrum antibiotics
[6,12,13]. Furthermore, a study reported that guideline-
adherent therapy in the management of nosocomial pneu-
monia, including MRSA HCAP was associated with
increased mortality, hypothesized to be due to drug toxic-
ities from aminoglycoside and colistin [13]. Over one-third
(37%) of the non-MRSA pneumonia patients were identi-
fied as HCAP by definition and 28% were given anti-MRSA
therapy. By applying Shorr’s scoring scheme, unnecessary
prescribing of anti-MRSA therapy in low risk patients
without MRSA pneumonia could have been reduced by
20%. Among the 11% of “low risk” patients who had MRSA
pneumonia in our cohort, outcomes were similar regardless
of receipt of empiric anti-MRSA therapy.
Vancomycin was the most commonly prescribed anti-
MRSA therapy. Although 90% of MRSA pneumonia
patients fit the definition of HCAP, the initiation rate of
empiric anti-MRSA therapy was suboptimal at 68%,
underscoring the need to improve early recognition of
at-risk patients. By using the scoring system to guide
empiric therapy, an additional 30% (40/134) of medium
or high risk patients with MRSA pneumonia would have
been promptly started on effective therapy. However, it
is notable that a delay of 3 days in initiating anti-MRSA
therapy did not lead to negative outcomes even among
the subgroup of critically ill patients (APACHE II ≥18)
with more severe presentation (n = 37), although, the
number of patients in this subgroup is small and most
received vancomycin therapy. It is possible that empiric
therapy with non-vancomycin alternatives (ie. linezolid
or ceftaroline) may alter outcomes in this subgroup and
therefore deserves to be studied further.
Limitations
This study has several limitations. First, our findings
may not be applicable to all settings or patient popula-
tions due to the retrospective, single center design. We
were unable to control for potentially confounding vari-
ables on outcomes such as antibiotic dosing and man-
agement of concurrent infections. MRSA grown from
the respiratory culture may not represent the causative
pathogen; however, we attempted to limit this possibil-
ity by including only patients who had MRSA as the
sole pathogen from culture.
We included culture negative patients in the non-MRSA
group in order to capture all those who presented to the
hospital with pneumonia and received antibacterials for
greater than 48 hours. Of the 106 patients who were culture
negative in the non-MRSA group, 27/106 (25%) received
empiric anti-MRSA therapy with the median duration of
4 days (IQR 1, 5.25). Outcomes were similar between those
Table 4 Comparison of patient characteristics and
outcomes of those with MRSA pneumonia who received
empiric vs directed anti-MRSA therapy
Characteristics Empiric
n = 88 (%)
Directed
n = 46 (%)
p value
Age [median (IQRa)]* 81 (72.3,88) 85.5 (69.8,93) 0.35
Residence prior to admission
Home 15 (17) 20 (43) 0.004
SNF 72 (82) 26 (57) 0.004
APACHE II score [mean, SDb]Y 17.9 ± 6.9 13.1 ± 5.2 <0.0001
PSI score [mean, SD]Y 153.4 ± 36.82 131.3 ± 34.9 0.0011
Mechanical ventilation 33 (38) 14 (30) 0.45
Duration of mechanical
ventilation [median IQR]*
3 (2,7) 6 (2.5,20.75) 0.064
Vasopressor use 37 (42) 8 (17) 0.0041
Outcomes
Time to reach clinical
stability [median (IQR)]*
7 (4,10) 6 (3.5,11.5) 0.47
Clinical response 55 (63) 35 (76) 0.12
Mortality at 28 days 24 (27) 5 (11) 0.029
Readmission within 30 days 11 (17) 7 (18) 0.79
Length of hospital stay
of survivors [median (IQR)]*
10 (6,15) 8.5 (7,14.3) 0.50
NOTE: aIQR = interquartile range; bSD = standard deviation; SNF = skilled nursing
facility; PSI = Pneumonia Severity Index; APACHE= Acute Physiology and Chronic
Health Evaluation.
Chi-square test done for categorical variables; p value < 0.05 denotes significance.
*Wilcoxon-Mann-Whitney test, p value < 0.05 denotes significance.
YStudent’s t-test, p value < 0.05 denotes significance.
Table 5 Risk factors predictive of 28d mortality in patients
with MRSA pneumonia by multivariate logistic regression
OR (95% CI) p value
Receipt of empiric anti-MRSA therapy 1.634 (0.461 - 5.793) 0.4468
Renal dysfunction 2.797 (0.838 - 9.343) 0.0946
Mechanical ventilation 2.747 (0.941 - 8.024) 0.0646
Vasopressor requirement 3.602 (1.078 - 12.039) 0.0374
APACHE II score 1.087 (0.987 - 1.198) 0.0903
NOTE: APACHE = Acute Physiology and Chronic Health Evaluation.
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with negative cultures who received empiric anti-MRSA
(n = 27) vs those did not (n = 79): favorable response in
25/27 (93%) vs 77/79 (97%), length of hospital stay
(median: 6 vs 5 days). This data confirms that MRSA was
not a likely pathogen in the culture-negative cohort and
that anti-MRSA therapy was not needed in that group.
The definition of pneumonia used in this study was
the CDC definition published in 2008. After our study
had been completed, an updated definition was pub-
lished in January 2014. Since the clinically defined pneu-
monia criteria remained the same and our first inclusion
criteria was diagnosis of pneumonia regardless of culture
results, we believe our screening criteria for inclusion
into the study remains applicable. We acknowledge that
the use of ICD-9 codes to identify patients can be in-
accurate due to coding bias; however, we have attempted
to rectify this limitation by including only patients who
have met the clinical definition of pneumonia per the
CDC criteria. Lastly, readmission rates could not be cap-
tured consistently as we do not have a closed healthcare
system in which patients may be readmitted to the other
institutions.
Conclusions
Utilization of the HCAP definition to determine patients
at risk for MRSA infection leads to excessive prescribing
of anti-MRSA antibiotics. The Shorr’s risk scoring scheme
improves identification of patients at high risk and low
risk for MRSA pneumonia presenting to the hospital;
however, 22% deemed to be at medium risk did not have
MRSA. Based on findings from our elderly cohort, inclu-
sion of additional variables of history of pneumonia within
1 year of admission, history of MRSA infection, and high
PSI score strengthen the utility of this new scoring system.
MRSA pneumonia patients present more acutely ill and
have worse outcomes compared to their non-MRSA co-
hort. Receipt of empiric anti-MRSA therapy, primarily
vancomycin, did not improve outcomes for patients with
MRSA pneumonia. Prospective studies evaluating the treat-
ment benefit of non-vancomycin alternatives as empiric
therapy are needed.
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